NAD+
Nicotinamide Adenine Dinucleotide / NAD
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme present in every living cell, functioning as an essential electron carrier in mitochondrial energy production and as a substrate for sirtuins, PARPs, and CD38 enzymes involved in DNA repair and cellular signaling. Declining NAD+ levels are strongly associated with aging and metabolic dysfunction, making NAD+ repletion a major focus of longevity research. It is administered via IV infusion, subcutaneous injection, or oral precursors (NMN, NR) in anti-aging and neurological research protocols.
작용 메커니즘
Essential coenzyme present in all living cells. Central to cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair (PARP enzymes), epigenetic regulation (sirtuins), and calcium signaling. Levels decline ~50% between ages 40-60.
연구 프로토콜
연구 용도만 사용 가능. 의학적 조언은 아닙니다.
Research protocols use 250-750mg via IV infusion over 2-4 hours. Subcutaneous protocols use 50-100mg daily. Intranasal formulations under investigation. IV sessions typically weekly for 4-8 weeks, then monthly maintenance.
연구 노트
Clinical Research Status
NAD+ IV therapy is actively studied in clinical trials for conditions including chronic fatigue, neurodegenerative diseases, substance use disorders, and age-related metabolic decline. The precursors NMN and NR have multiple ongoing Phase I/II trials examining bioavailability, safety, and effects on aging biomarkers. While IV NAD+ clinics have proliferated globally, FDA-approved therapeutic indications remain limited to experimental and integrative medicine settings.
Key Published Findings
Research has demonstrated that NAD+ levels decline by approximately 50% between ages 40 and 60, correlating with mitochondrial dysfunction and increased disease susceptibility. Studies in animal models show that NAD+ repletion restores mitochondrial function, improves insulin sensitivity, and extends healthspan markers. Human trials with NR supplementation have confirmed dose-dependent increases in blood NAD+ levels with good tolerability, though functional clinical endpoints are still being validated.
Safety Profile
IV NAD+ infusions are generally well-tolerated but commonly produce transient side effects including chest tightness, nausea, abdominal cramping, and flushing during infusion, which are managed by slowing the drip rate. Oral precursors NMN and NR show excellent safety profiles in clinical doses of 250-1000mg daily with minimal adverse events reported. Theoretical concerns exist about long-term high-dose NAD+ supplementation potentially fueling growth of existing cancers, though clinical evidence for this remains inconclusive.
Drug Interactions & Contraindications
NAD+ may interact with blood pressure medications due to its vasodilatory effects during IV administration. Caution is advised with concurrent use of chemotherapeutic agents, as NAD+-dependent PARP inhibitors may have altered efficacy. Patients with active malignancies should consult their oncologist before beginning NAD+ therapy given the theoretical role of NAD+ in supporting cellular proliferation.
Comparison to Related Compounds
NMN (nicotinamide mononucleotide) is a direct NAD+ precursor requiring one enzymatic step for conversion, offering potentially faster NAD+ elevation than NR. NR (nicotinamide riboside) has more published human clinical trial data and established commercial availability as a supplement (TruNiagen, Elysium). Direct IV NAD+ bypasses the need for enzymatic conversion entirely but requires clinical administration and produces more acute side effects than oral precursors.
Community Observations
Users of IV NAD+ commonly report initial sessions being uncomfortable due to nausea and chest tightness, with subsequent sessions becoming more tolerable as the body adapts. Many practitioners administer loading protocols of 500-1000mg IV daily for 3-5 days followed by monthly maintenance infusions. The biohacking community frequently combines NAD+ protocols with resveratrol and fasting to maximize sirtuin activation and perceived anti-aging benefits.
반감기
~45 minutes (IV)
재조성
Sterile saline for IV; bacteriostatic water for SubQ
보관
건조한 상태
Refrigerate 2-8C. Protect from light.
재조성된 상태
Use within 24 hours of preparation (IV). SubQ: within 7 days.
미국 법적 상태
또는 알려진 이름으로
자주 묻는 질문
NAD+란 무엇인가요?
NAD+ (nicotinamide adenine dinucleotide) is a critical coenzyme present in every living cell, functioning as an essential electron carrier in mitochondrial energy production and as a substrate for sirtuins, PARPs, and CD38 enzymes involved in DNA repair and cellular signaling. Declining NAD+ levels are strongly associated with aging and metabolic dysfunction, making NAD+ repletion a major focus of longevity research. It is administered via IV infusion, subcutaneous injection, or oral precursors (NMN, NR) in anti-aging and neurological research protocols.
NAD+는 어떻게 작용하나요?
Essential coenzyme present in all living cells. Central to cellular energy metabolism (glycolysis, TCA cycle, oxidative phosphorylation), DNA repair (PARP enzymes), epigenetic regulation (sirtuins), and calcium signaling. Levels decline ~50% between ages 40-60.
NAD+의 미국 규제 현황은 어떤가요?
Supplement (not FDA-regulated as drug)
NAD+의 반감기는 얼마인가요?
~45 minutes (IV)
NAD+의 다른 이름은 무엇인가요?
Nicotinamide Adenine Dinucleotide, NAD
Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.
전체 공지사항 읽기